Citations

Clear

2504 citation(s) found for "Wu, Benjamin".

Retreatment with First-Generation Selective RET Inhibitors in RET -Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry
Marinello, A., Rotow, Julia K., Lomibao, Meghanne , Miliziano, Daniela , Leporati, Rita , Feng, Jamie , Metro, Giulio , Brandão, Mariana , Gorría, Teresa , Nassar, Amin H. , Fila, Matteo, Fallet, V., Ricciuti, Biagio, Taylor, Skyler, Remon, Jordi, Planchard, David, Florez, Narjust, Besse, Benjamin, Drilon, Alexander D., Aldea, Mihaela, Nassar, Amin H. , Rotow, Julia , Metro, Giulio , Marinello, Arianna , Marinello, Arianna , Rotow, Julia K. , Citarella, Fabrizio , Fila, Matteo , Fallet, Vincent , Ricciuti, Biagio , Taylor, Skyler , Remon, Jordi , Planchard, David , Duma, Narjust , Besse, Benjamin , Drilon, Alexander , Aldea, Mihaela , Feng, Jamie , Citarella, Fabrizio , Ricciuti, Biagio , Planchard, David , Florez, Narjust , Besse, Benjamin , Aldea, Mihaela

Mayo Clinic

Clinical Cancer Research | April 7, 2026 | Volume: 32 | Issue: 13 | Pages: 2637-2643

10.1158/1078-0432.ccr-25-4814 | PMID 41945500 Get It

Abstract Purpose: In RET-rearranged non–small cell lung cancer (NSCLC), treatment options after first-generation selective RET inhibitors (SRI) are limited, and the value of SRI retreatment remains unclear. This study evaluates outcomes of SRI retreatment. Experimental Design: This multicenter retrospective study included patients with advanced RET-rearranged NSCLC who received ≥2 SRI-based therapy lines. Of 411 SRI-treated patients, 41 (10%) underwent SRI retreatment. Outcomes included objective response rate (ORR), progression-free survival (PFS), 6-month PFS, time to treatment failure, adverse events (AE). Results: Among 41 patients, 14 (34%) discontinued the initial SRI because of toxicity and 27 (66%) because of progression. After discontinuation for toxicity, all switched to an alternate SRI, achieving an ORR of 67%, median PFS of 9.9 months, and 6-month PFS of 80.3%. AEs reoccurred in nine patients (64%), with grade ≥3 AEs in 3 (21%) who switched at full dose. Among patients who discontinued because of progression, SRI monotherapy (n = 13) achieved an ORR of 23%, median PFS of 7 months, and 6-month PFS of 61.5%. Benefit was observed in patients with brain-only or oligoprogressive disease or dose reduction on first SRI. Combination therapy (n = 14; targeted agents, n = 11; chemotherapy, n = 3) achieved an ORR of 39%, median PFS of 4 months, and 6-month PFS of 27.3%. Conclusions: Same-class SRI switch after toxicity is feasible and clinically active but warrants cautious, dose-adjusted switching to mitigate toxicities. The efficacy of SRI rechallenge after progression seems limited overall. However, selected patients, such as those with brain-only or oligoprogressive disease, may derive benefit.
Risk Factors for Postoperative Cerebrospinal Fluid Leak Following Endoscopic Transsphenoidal Surgery for Craniopharyngioma: A Multicenter Cohort Study with a Contemporary Surgeon Practice Survey
Celda, María Peris, Karsy, Michael, Evans, James J, Kim, Albert H, Kim, W, Bergsneider, Marvin , Pacione, Donato , Gardner, Paul A. , Mukherjee, Raj, Liu, Connor J. , Cheok, Stephanie , Zwagerman, Nathan T. , Christenson, Charles, Blackburn, Spiros, Kshettry, Varun R, Wu, Kyle C, Prevedello, Daniel, Barkhoudarian, Garni, Fernandez-Miranda, Juan C., Zada, Gabriel, Benjamin, Carolina , Catalino, Michael Paul, Mamelak, Adam N, Furlan, André Beer, Zenonos, Georgios, Mendoza, Michelle Magana, Little, Andrew S, Gompel, Jamie J., Karsy, Michael , Palit, Sandhya R. , Shinya, Yuki , Karsy, Michael , Evans, James J., Chicoine, Michael , Kim, Albert H , Patel, Bhuvic , Kim, Won Bae , Gardner, Paul, Mukherjee, Debraj , Liu, C P, Blackburn, Spiros , Kshettry, Varun R. , Rennert, Robert C , Couldwell, William T. , Morshed, Ramin A. , Barkhoudarian, Garni , Fernandez‐Miranda, Juan C. , Zada, Gabriel , BENJAMIN, CAROLINA, Mamelak, Adam N. , Zenonos, Georgios A. , Little, Andrew S. , Gompel, Jamie J. Van

Mayo Clinic

No container title available | April 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9285619/v1 | PMID 41994110 Get It

Abstract Purpose: This multicenter, multi-surgeon retrospective study aimed to identify risk factors for postoperative cerebrospinal fluid (CSF) leak following endonasal resection of craniopharyngioma, while evaluating the "perception gap" through a surgeon survey. Methods: A retrospective review was conducted on 416 patients who underwent endoscopic transsphenoidal surgery (ETS) for craniopharyngioma from 20 institutions. Factors were compared between patients with and without postoperative CSF leak, and between Early (2007-2015) and Late (2016-2025) Epochs. Complementing the clinical data, a survey of 19 neurosurgeons captured expert perspectives on risk stratification and management strategies. Results: Overall postoperative CSF leak rate was 13.5% (56/416 patients). Univariate analysis identified predominantly cystic tumors (34% vs. 21%, p = 0.034)and intraoperative lumbar drain (LD) use ( p < 0.028) as associated with postoperative CSF leak. BMI ( p = 0.587), prior surgery ( p = 0.576), and tumor size ( p = 0.363) were not significant. In the multivariable analysis, LD use was associated with a higher postoperative CSF leak rate (OR 1.91, 95% CI 1.06–3.46; p = 0.030). Between Epochs, nasoseptal flap (NSF) utilization increased from 70.7% to 87.6% ( p <0.001). NSF was protective (OR 0.28, 95% CI 0.07–0.92; p = 0.037) in the Early Epoch; no factors were significant in the Late Epoch. The surgeons’ survey identified prior surgery and intraoperative high flow leaks as primary risks; however, their LD protocols diverged from clinical data. Conclusion: Despite increased use of NSF, CSF leak persists. The study highlights a significant divergence between expert perception and clinical data regarding lumbar drains.
Predicted versus observed outcomes in the ALT-FLOW early feasibility study
Fioretti, Francesco , Gray, William A, Hibbert, B, Lindenfeld, JoAnn, Tedford, Ryan J, Zahr, Firas, Butler, Javed , Butler, Javed , Gray, William A. , Hibbert, Benjamin , Lindenfeld, JoAnn , Tedford, Ryan J. , Zahr, Firas

Mayo Clinic

ESC Heart Failure | April 3, 2026 | Volume: 13 | Issue: 3 | Pages: No page available

10.1093/eschf/xvag101 | PMID 42257333 Get It

Abstract Background and Aims Whether hemodynamic and symptomatic benefits of the APTURE left atrial-to-coronary sinus shunt translate into clinical outcome benefit in heart failure with left ventricular ejection fraction &gt;40% remains unknown. Methods In this post hoc analysis of ALT-FLOW EFS patients undergoing APTURE implantation, Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) score-predicted 1-year all-cause mortality was compared with observed mortality by Kaplan-Meier analysis of adjudicated events. Heart failure hospitalization (HFH) rates were compared for the 12 months before vs after implantation. Additional analyses included stratification by baseline sodium-glucose cotransporter 2 inhibitor (SGLT2i) use and N-terminal pro-B-type natriuretic peptide (NT-proBNP), recurrent HFH cumulative hazard estimation (Nelson-Aalen), and H2FPEF score calculation. Results Among 95 patients (mean age 70.9 ± 8.5 years; 50% women; 93% New York Heart Association Class III; 85.9% with H2FPEF score &gt;3), MAGGIC-predicted 1-year mortality was 13.0%. Observed 1-year survival was significantly higher than predicted (94.7% vs 87.0%; P=0.04), consistent across SGLT2i subgroups (log-rank P=0.59). The proportion of patients with HFH declined from 37.9% pre implantation to 9.6% post implantation (P&lt;0.0001), with event rates falling from 0.61 to 0.21 per patient-year (P&lt;0.001) and a 1-year cumulative hazard of recurrent HFH of 0.19 (95% confidence interval, 0.12-0.31). HFHs were evenly distributed across NT-proBNP strata. Conclusions In ALT-FLOW EFS, observed 1-year mortality was lower than MAGGIC-predicted mortality, and post implantation HFH rates were lower than pre implantation rates. These hypothesis-generating findings will require confirmation in the randomized, sham-controlled ALT-FLOW II trial.
Abstract 4661: Expression of the ferroptosis suppressor FSP1 but not GPX4 shows significant adverse prognostic effect in diffuse large B-cell lymphoma with wild-type TP53
Lyu, Beibei, Xu-Monette, Zijun Yidan, Zhao, Xiaoxian X., Chen, Ming, Visco, Carlo, Dybkaer, Karen, Wang, Chang , Au, Qingyan , Nunns, Harry , Pan, Zenggang, Montes-Moreno, Santiago, Bernal-Mizrachi, Leon, Zu, Youli , Zhang, Shanxiang , Chen, Weina , Li, Yong, Zu, Youli , Xu‐Monette, Zijun Y. , Hsi, Eric D. , Visco, Carlo , Tzankov, Alexandar , Dybkær, Karen , Wang, Mu‐En , Pan, Zenggang , Parsons, Benjamin M. , Montes‐Moreno, Santiago , Zhan, Fenghuang , Møller, Michael , Bernal‐Mizrachi, Leon , Bhagat, Govind , Young, Ken H.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 4661-4661

10.1158/1538-7445.am2026-4661 Get It

Abstract Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common type of malignant lymphoma. Previous studies have shown that DLBCL cells are susceptible to GPX4 (Glutathione peroxidase 4)-regulated ferroptosis, an iron-dependent type of programmed cell death characterized by increased reactive oxygen species and excessive lipid peroxidation. In addition to GPX4, FSP1 (Ferroptosis suppressor protein 1, previously known as AIFM2) is a glutathione-independent repressor of ferroptosis that has shown prognostic significance in solid tumors. In this study, we aimed to reveal the significance of GPX4 and FSP1 in DLBCL. Patients and Methods: We performed immunohistochemistry (IHC) for GPX4 and FSP1 in a large cohorts of patients with de novo DLBCL, and evaluated their cytoplasmic and nuclear expression. Prognostic analysis was performed for FSP1 and GPX4 expression in patients treated with rituximab (R)-CHOP or CHOP chemotherapy, respective of TP53 mutation status, as p53 regulates ferroptosis and TP53 mutation is associated with poorer prognosis in DLBCL. Results: FSP1 expression with a ≥10% cutoff was positive in 42.3% of DLBCL cases. Patients with TP53 mutations had a non-significant trend of higher mean FSP1 expression than those with wild-type (Wt) TP53 (P=0.11). Prognostic analysis revealed that cytoplasmic FSP1+ expression was associated with significantly poorer overall survival and progression-free survival in Wt-TP53 DLBCLs treated with R-CHOP (P=0.016 and P=0.003, respectively), and only showed non-significant unfavorable trends in TP53 mutated DLBCLs and patients treated with CHOP. In contrast, GPX4 expression did not show a significant unfavorable prognostic effect in DLBCL, and in fact, was associated with a non-significant trend of better survival. Previously we have quantified immune cell abundance and PD-1/PD-L1 expression in the tumor microenvironment of the study cohort using multiplex fluorescent IHC. Correlative analysis found that FSP1+ patients had significantly higher mean and median abundance of CD68+ cells (both M1 and M2 macrophages) and CD11c+ cells than FSP1- patients. Further analysis in Wt-TP53 and mutated TP53 subcohorts found that only in the TP53 mutated DLBCL subcohort, FSP1 expression was associated with significantly higher mean and median CD163-CD68+ (M1) and overall CD68+ macrophages, whereas in the Wt-TP53 DLBCL subcohort, FSP1 expression was associated with significantly higher median (but not mean) CD163+CD68+ (M2) macrophages and CD11c+ cells. Summary: Cytoplasmic FSP1 expression but not GPX4 had significantly adverse prognostic effect in patients with Wt-TP53 DLBCL treated with standard immunochemotherapy. Our results also suggest that in addition to ferroptosis regulation, macrophage abundance was relevant for the prognostic effects of FSP1 expression. Citation Format: Beibei Lyu, Zijun Xu-Monette, Xiaoxian X. Zhao, Eric D. Hsi, Ming Chen, Carlo Visco, Alexandar Tzankov, Karen Dybkaer, Mu-En Wang, Chang Wang, Qingyan Au, Harry Nunns, Zenggang Pan, Benjamin Parsons, Santiago Montes-Moreno, Fenghuang Zhan, Michael B. Møller, Leon Bernal-Mizrachi, Youli Zu, Shanxiang Zhang, Weina Chen, Govind Bhagat, Yong Li, KEN H. YOUNG. Expression of the ferroptosis suppressor FSP1 but not GPX4 shows significant adverse prognostic effect in diffuse large B-cell lymphoma with wild-type TP53 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 4661.
Abstract 6289: Targeted sequencing of common cancer susceptibility genes reveals germline variants in African prostate cancer patients.
Onyia, Abimbola F. , Okwuchi, Freeman, Divine, Sylvester, Olasehinde, Olutola Esther, Yahaya, Ayinde, Salako, A A, Zakari, Aminu, Bassey, Iya, Petershie, Bernard, GANDAHO, Isidore, Brun, Luc, Sanni, Tore, Coulibaly, Sidi, Coulibaly, Noel, Fakayode, Michael, Issoufou, Coulibaly, Gbonon, Valérie Mbengue, Benjamin, Kouamé, Evrard, Yao, Coleman, Peter, Ajumbo, Victor, Wattanga, Lilac, Nyambega, Benson Ochieng, Odedina, Folakemi T., Campos, Opeyemi Christianah De , Titiloye, Nicholas Akinwale , Gandaho, Isidore, Noel, Coulibaly, Fakayode, Michael Karington , Kouame, Benjamin , Cassell, Ayun , Nyambega, Benson , Rotimi, Solomon O.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 6289-6289

10.1158/1538-7445.am2026-6289 Get It

Abstract Background: Prostate cancer (PCa) is the leading cause of cancer-related deaths globally and disproportionately affects men of African ancestry. African men often present at younger ages and with more aggressive disease, and approximately half of the PCa risk has been attributed to genetic factors. Africa is the most genetically diverse region of the world, and even within the continent, populations show important differences in allele frequencies and patterns of pathogenic variation. Despite this diversity, African men remain underrepresented in genomic studies, creating significant gaps in knowledge that limit precision medicine efforts. Methods: A total of 182 prostate cancer patients were recruited from teaching hospitals in Benin, Côte d’Ivoire, Ghana, Kenya and Nigeria. 50 cancer susceptibility genes using the Aviseq ONCO50 panel and the Illumina MiSeq platform. Variant calling was performed using an in-house Snakemake workflow, followed by additional bioinformatic steps to distinguish true PMS2 variants from PMS2CL-related artifacts. Pathogenicity assessment relied on annotations from ClinVar and LOVD databases. Results: Pathogenic and likely pathogenic variants were detected in 31.3% of the study group identified in 26 genes. The five most frequently altered genes were RAD50, PTCH1, MSH6, MUTYH, and NF1. Nigerian patients accounted for 52.6 percent of all pathogenic variants, with recurrent alterations observed in MSH6, MUTYH, NF1, and PTCH1. In contrast, pathogenic BRCA1 and BRCA2 variants were observed primarily in patients from Kenya, Benin, and Côte d’Ivoire. Several frameshift, nonsense, and splice-site variants identified in this study have not been previously reported in African populations.[SR1] Conclusion: This study provides one of the most detailed assessments of inherited cancer susceptibility gene variants in African PCa patients. The findings reveal substantial regional variation in the spectrum of pathogenic variants and highlight population-specific genomic signatures that may contribute to the unequal burden of PCa in men of African ancestry. These data emphasize the importance of expanding genomic research efforts within Africa to strengthen precision oncology and reduce global PCa disparities. Citation Format: Abimbola F. Onyia, Freeman Okwuchi, Opeyemi C. De Campos, Sylvester Divine, Olutola Olasehinde, Ayinde Yahaya, Ayo Salako, Aminu Zakari, Iya Bassey, Nicholas Titiloye, Bernard Petershie, Isidore GANDAHO, Luc Brun, Tore Sanni, Safiatou Coulibaly, Noel Coulibaly, Michael Fakayode, Coulibaly Issoufou, Valérie Gbonon, Kouame Benjamin, Yao Evrard, Peter Coleman, Ayun Cassell, Victor Ajumbo, Lilac Wattanga, Benson Ochieng Nyambega, Folakemi T. Odedina, Solomon Rotimi. Targeted sequencing of common cancer susceptibility genes reveals germline variants in African prostate cancer patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6289.
Abstract 5423: A Bayesian framework for evaluating somatic copy number variants into comparative genomic analysis of multifocal non-small cell lung cancer.
Teigen, Claire, Lo, Ying-Chun, Gupta, Sounak, Smoley, Stephanie A., Kateb, Hussam Al, Sivasankaran, Gopi, Kipp, Benjamin, Rumilla, Ande M., Zheng, Gang , Halling, Kevin, Geiersbach, Katherine, Teigen, Claire, Lo, Ying‐Chun , Pitel, Beth A. , Al‐Kateb, Hussam , Kipp, Benjamin R. , Zheng, Gang, Halling, Kevin C. , Geiersbach, Katherine B.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 5423-5423

10.1158/1538-7445.am2026-5423 Get It

Abstract Introduction: Clinical staging of multifocal non-small cell lung cancer (NSCLC) is facilitated by comparative genomic analysis of separate tumor nodules, but the role of genome-wide copy number profiling for this purpose is uncertain. Methods: We analyzed single nucleotide variants (SNVs), gene fusions, small copy number variants (gene amplifications and homozygous deletions) (sCNVs), and large-scale copy number variants (lCNVs) in a retrospective cohort of 34 patients with &gt;1 lung cancer nodule tested on a previously validated tumor-only 515-gene next generation sequencing (NGS) panel (MayoComplete Solid Tumor Panel). For patients with &lt;2 shared SNVs, a Bayesian approach was formulated to calculate the probability of shared versus independent events occurring in different tumor nodules in the same patient. The prevalence of specific lCNVs in NSCLC was derived from an independent dataset of 100 NSCLC peers tested by the same panel, and the prevalence of SNVs, fusions, and sCNVs in NSCLC was derived from publicly available data. Alterations unique to different tumor nodules and suspected germline alterations were excluded from the Bayesian analysis. Results: There were 54 total comparisons for 34 patients. Eleven of the patients (32.4%) had &gt;=2 shared SNVs along with one or more shared lCNVs also identified in each patient. Eight patients (23.5%) had no shared SNVs, gene fusions, sCNVs, or lCNVs. Using the Bayesian approach for the remaining fifteen (44.1%) patients with at least one shared alteration (SNVs, sCNVs, and lCNVs), the probability of clonal relatedness ranged from 73% for a shared whole arm or whole chromosome lCNV to &gt;99% for tumors with two or more shared alterations including multiple or complex lCNVs and SNVs. Whole chromosome or whole arm lCNVs were sometimes shared between tumor nodules with different driver SNVs. Conclusions: Incorporating lCNVs into comparative genomic analysis provides additional evidence of clonal relatedness in a subset of multifocal NSCLCs. However, differences in bioinformatics pipelines for calling lCNVs, concerns over the imprecision of genome-wide copy number profiling, and uncertainty regarding the temporal relationship between lCNVs and carcinogenesis (including somatic events possibly related to “field cancerization”) create challenges for integrating lCNVs into comparative genomic analysis with standard clinical workflows for tumor-only NGS on paraffin embedded tissue sections. Our simplified approach mitigates some of the uncertainty introduced by incorporating lCNVs into clonality determination. Citation Format: Claire Teigen, Ying-Chun Lo, Sounak Gupta, Stephanie Smoley, Beth Pitel, Hussam Al Kateb, Gopi Sivasankaran, Benjamin Kipp, Ande Rumilla, Gang Zheng, Kevin Halling, Katherine Geiersbach, . A Bayesian framework for evaluating somatic copy number variants into comparative genomic analysis of multifocal non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5423.
Abstract 215: Primary cardiac lymphoma and HIV: A nationwide analysis of hospitalizations.
Hozayen, Omar, Hozayen, Jay, Behers, Benjamin, Stephenson-Moe, Christoph, Miller, Matthew , Herrera, Laura De Jesus, Jad, Anas A Abu, Kammer, Rheiner, Idriss, Mohab, Aboutaleb, Ahmed, Roumia, Bashar, Riano, Patricia, Neira, Nicolas Riveros, Hartenstein, Brooke, Taylor, Robert , Espinal, M Rosario, Behers, Brett M. , Hozayen, Alya, Ibrahim, Mohamed , Hamad, K M, Hozayen, Jay, Behers, Benjamin J. , Stephenson-Moe, Christoph A. , Hameed, Maha , Miller, Matthew, Rivero, Patricia Riano, Taylor, Robert, Hamad, Karen M.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 215-215

10.1158/1538-7445.am2026-215 Get It

Abstract Background: Primary Cardiac Lymphoma (PCL) is an exceptionally rare malignancy. While clinical case reports have postulated an association with human immunodeficiency virus (HIV), large-scale epidemiological data corroborating this link are limited. Objective: To determine whether HIV is associated with increased prevalence of PCL in a large, nationally representative sample of US hospitalizations. Methods: We performed a retrospective, cross-sectional analysis using the Healthcare Cost and Utilization Project National Inpatient Sample from 2016 to 2019, representing approximately 35 million unweighted hospitalizations. Hospitalizations were identified using a proxy definition for PCL, requiring ICD-10-CM codes for both cardiomyopathy (I42.*) and extranodal non-Hodgkin lymphoma (i.e., C83.39, C85.99). HIV status was identified using codes B20-B24 and Z21. We compared the prevalence of PCL in hospitalizations with versus without HIV and calculated odds ratios using Fisher’s Exact Test, reporting corresponding 95% confidence intervals (CI) and p-values. Results: We identified 569 hospitalizations meeting our operational definition for PCL out of 34,955,252 total discharges. The prevalence of PCL was significantly higher among hospitalizations with HIV (6.2 per 100,000) compared with those without HIV (1.6 per 100,000; p &lt; 0.0001). HIV was associated with a 3.86-fold increased odds of PCL (OR: 3.86; 95% CI: 2.23-6.70; p &lt; 0.0001). Conclusion: In this nationwide analysis of 35 million hospitalizations, HIV was strongly associated with a higher prevalence of PCL. Hospitalizations with HIV had nearly 4-fold higher odds of PCL, as defined by co-occurrence of cardiomyopathy and extranodal lymphoma, compared with hospitalizations without HIV. This population-level finding evinces the association previously suggested in clinical case reports. Citation Format: Omar Hozayen, Jay Hozayen, Benjamin Behers, Christoph Stephenson-Moe, Maha Hameed, Matthew Miller, Laura De Jesus Herrera, Anas Abu Jad, Rheiner Kammer, Mohab Idriss, Ahmed Aboutaleb, Bashar Roumia, Patricia Riano, Nicolas Riveros Neira, Brooke Hartenstein, Robert Taylor, Manuel Rosario Espinal, Brett M. Behers, Alya Hozayen, Mohamed Ibrahim, Karen Hamad. Primary cardiac lymphoma and HIV: A nationwide analysis of hospitalizations [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 215.
Consensus recommendations for malignant histiocytic neoplasms (histiocytic, Langerhans, and interdigitating dendritic cell sarcomas)
Goyal, Gaurav, Abla, Oussama , Chan, John K. C. , Diamond, Eli L. , Durham, Benjamin H. , Emile, J, Girschikofsky, Michael , Go, Ronald S., Jaffe, Elaine S. , Go, Ronald S. , Emile, Jean‐François , Goyal, Gaurav , Goyal, Guarav , Chan, John , Durham, Benjamin , Emile, Jean-François , Go, Ronald S , Hornick, Jason L , Jaffe, Elaine S , McClain, Kenneth L , Picarsic, Jennifer L , Diamond, Eli L , Hornick, Jason L. , McClain, Kenneth L. , Rech, Karen L. , Picarsic, Jennifer

Mayo Clinic

Blood | March 31, 2026 | Volume: 148 | Issue: 3 | Pages: 275-288

10.1182/blood.2026033049 | PMID 41915766 Get It

Abstract Malignant histiocytic neoplasms (MHNs) are rare tumors derived from the mononuclear phagocyte system (MPS), encompassing histiocytic sarcoma, Langerhans cell sarcoma, interdigitating dendritic cell sarcoma, and other high-grade MPS lineage tumors. Despite advances in understanding histiocytic neoplasms, MHNs remain diagnostically challenging and lack standardized treatment algorithms. Current classification systems differ in lineage framing and fail to address mixed or ambiguous phenotypes, contributing to diagnostic uncertainty and inconsistent care. To address these gaps, the Histiocyte Society convened an international working group of pathologists and oncologists, including World Health Organization and International Consensus Classification contributors, to harmonize nomenclature, define minimum diagnostic criteria, and develop pragmatic treatment recommendations. Using a modified Delphi process and case-based review, the group formulated &gt;40 consensus statements spanning classification, pathology, molecular testing, clinical evaluation, and therapeutic strategies. Key recommendations include the adoption of a unified MHN designation, use of a minimum immunophenotypic panel, integration of broad molecular profiling, and the documentation of previous hematopoietic malignancy. Treatment algorithms emphasize surgical resection for unifocal disease and targeted therapy or immune checkpoint inhibition for multifocal disease when actionable mutations or programmed death ligand 1 expression are present. These consensus recommendations aim to reduce diagnostic ambiguity, standardize reporting, and improve outcomes for both pediatric and adult patients. Future priorities include international registries to refine risk stratification and biomarker-driven trials exploring targeted therapy, immunotherapy, and combination approaches.